Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ ...

CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech', 6990.HK) today announced that results from its ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination ...

The first half of this year has been riddled with market volatility and geopolitical tension. But 2025’s American Society of ...

Merck’s investigational KRAS G12C inhibitor, MK-1084 shows antitumor activity in phase 1 trial of patients with advanced CRC and NSCLC whose tumours harbour KRAS G12C mutations Rahway, New Jersey ...

with chemotherapy (cisplatin/carboplatin and pemetrexed). BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations ...

A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set—T790M negative (n = 62) and T790M positive (n = 2). The median OS in the ...